2Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock [J]. Cochrane Database Syst Rev, 2002, 1 (1): CD001090. DOI: 10.1002/14651858. CD001090.
3Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2013, 39 (2): 165- 228. DOI: 10.1007/s00134-012-2769-8.
4Jesdinsky HJ, Tempel G, Castrup HJ, et al. Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinnpurulent peritonitis [J]. Klin Wochenschr, 1987, 65 (23): 1132-1138.
5Dominioni L, Dionigi R, Zanello M, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater [J]. Arch Surg, 1991, 126 (2): 236-240. DOI: 10.1001/ archsurg. 1991.01410260126018.
6Rodrignez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery [J]. Shock, 2005, 23 (4): 298-304. DOI: 10.1097/Ol.shk.0000157302.69125.f8.
7Dominioni L, Bianchi V, Imperatori A, et al. High-dose intravenous IgG for treatment of severe surgical infections [J].Dig Surg, 1996, 13 (4-5): 430-434. DOI: 10.1159/000172479.
8Hentrich M, Fehnle K, Ostermann H, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial [J]. Crit Care Med, 2006, 34 (5): 1319-1325. DOI: 10.1097/01.CCM. 0000215452.84291.C6.
9Darenberg J, Ihendyane N, SjOlin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial [J]. Clin Infect Dis, 2003, 37 (3): 333-340. DOI: 10.1086/376630.
10De Simone C, Delogn G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients [J]. Crit Care Med, 1988, 16 (1): 23-26.
